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mTOR: Alzheimer’s disease prevention for APOE4 carriers
Ai-Ling Lin, David Allan Butterfield and Arlan Richardson
Alzheimer’s disease (AD) is the most common form 
of dementia and the 6th leading cause of death in the US. 
Inheritance of the Apolipoprotein ε4 (APOE4) allele is the 
strongest genetic risk factor for late-onset AD - APOE4 
carriers accumulate beta-amyloid (Aβ) and neurofibrillary 
tau tangles earlier and with more extensive pathology 
compared to non-carriers. However, decades before the 
aggregation of Aβ and tau, cognitively normal APOE4 
carriers have developed neurovascular deficits, including 
reduced cerebral blood flow (CBF) and impaired blood-
brain barrier (BBB) integrity [1]. The above indicates 
that brain physiology is altered in APOE4 carriers 
before clinical markers such as Aβ, tau pathology, and 
memory deficits appear, suggesting that vascular changes 
predispose APOE4 carriers to developing AD. Therefore, 
early interventions that can restore neurovascular deficits 
to normal could be critical in potentially preventing 
the development of AD-related neuropathology and 
cognitive impairment. In a recent study, using magnetic 
resonance imaging (MRI), Lin et al. reported that young, 
asymptomatic APOE4 targeted-replacement mice treated 
with rapamycin had restored CBF and BBB integrity 
to the level of wild-type controls [2]. The preserved 
vasculature was associated with amelioration of incipient 
learning deficits of the APOE4 transgenic mice. The 
significance of this discovery is that brain functions are 
pharmacologically reversible and AD potentially could be 
prevented in asymptomatic APOE4 carriers. 
Rapamycin is a drug approved by US Food and Drug 
Administration (FDA). It has been widely used in clinical 
settings and was originally used as an immunosuppressive 
agent to prevent rejection of organs in transplant patients. 
By 1991, Heitman and co-workers discovered a kinase, 
Target of Rapamyin (TOR) [3]. In mammals, the protein 
is specified as mammalian TOR, or mTOR. mTOR is 
the serine/threonine kinase that is the regulatory nexus 
in the response of eukaryote cells to nutrients, growth 
factors, and cellular energy status. Rapamycin is a mTOR 
inhibitor. A major breakthrough occurred in 2009 when 
it was shown that rapamycin, which reduced mTOR 
signaling, increased the lifespan of mice (see review in 
[4]). In addition, rapamycin has been shown to reduce 
a variety of cancers in mice as well as atherosclerosis 
in mouse models fed high fat diets as well as improve 
immunity in elderly humans [5]. As regard to the human 
central nervous system, several studies have shown that 
inhibition of mTOR by rapamycin treatment improves 
cognition, slows brain aging, and impedes the progress of 
neurodegenerative disorders through pathways associated 
with autophagy, glucose metabolism and mitochondrial 
functions [6].
Lin et al. demonstrated that mTOR inhibition 
reduced proinflammatory pathways in brain vasculature 
that otherwise impair BBB integrity in the APOE4 
transgenic mice [2]. Loss of BBB integrity is considered 
one of the initiating events that lead to AD-like 
pathological cascade in the APOE4 carriers [1]. Restoring 
BBB integrity is highly associated with improved CBF 
and preserved learning ability of the APOE4 transgenic 
mice [2]. In addition, Lin et al. previously reported 
that inhibition of mTOR activates endothelial nitric 
oxide synthase and causes the release of nitric oxide, a 
vasodilator, which in turn increases CBF [7]. In mice 
modeling human AD (hAPP (J20)), Lin et al. found 
that rapamycin restored their CBF and vascular density, 
which were associated with reduced accumulation of Aβ 
and cerebral amyloid angiopathy, and improved memory 
[7]. Collectively, these findings indicate that rapamycin 
alters neurovascular functions through multiple potential 
pathways. Because neurovascular defects are one of the 
earliest events that lead to AD-like pathology, mTOR 
inhibition might be an effective intervention to preserve 
brain vascular functions and consequently slow or prevent 
the progress of AD development. 
In conclusion, mTOR inhibition has been shown 
to increase lifespan and healthspan in various species. 
Rapamycin (or its derivatives, rapalogues) has been 
approved by the FDA since 1999 for various uses in 
humans, and these compounds have been given to cancer 
patients for relatively long periods of time with little 
change in the quality of life. Lin et al. further demonstrated 
that rapamycin restores and preserves neurovascular 
functions in the APOE4 transgenic mice using MRI. Their 
results may provide the basis for future AD prevention 
trials in human APOE4 carriers. 
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